[{"from": "human", "value": "Describe this molecule. [C][C][C][Branch1][Ring2][C][Ring1][Ring2][C][=Branch1][C][=O][N][Branch2][Ring1][O][C][=Branch1][C][=S][N][Ring1][Branch2][C][=C][N][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C][C][N][C][C][Ring1][=Branch1][C][=C][C][=Branch1][#Branch2][=C][Branch1][Branch1][N][=C][Ring1][=Branch1][C][#N][C][Branch1][C][F][Branch1][C][F][F]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable androgen receptor (AR) antagonist, with potential antineoplastic activity. Upon oral administration, AR antagonist TRC253 specifically binds to both wild-type and certain mutant forms of AR, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of growth of tumor cells in which AR is overexpressed and/or mutated. AR is often overexpressed and/or mutated in prostate cancers and plays a key role in proliferation, survival and chemoresistance of tumor cells."}]